PT-141 vs Melanotan II: A Derivative and Its Parent Compound

The short answer

Melanotan II is a non-selective melanocortin agonist, engaging several receptors in the family including MC1R, MC3R and MC4R. PT-141 is a derivative of it with a different selectivity profile, weighted away from the MC1R activity that dominates the Melanotan II literature. Same structural family, different receptor emphasis.

Why selectivity is the whole story

The melanocortin receptors are a family whose members are expressed in different tissues and coupled to different downstream pathways. Within that family, changing which receptors a molecule preferentially engages changes what is observed - not by making the compound stronger or weaker, but by moving the activity to a different part of the system. PT-141's existence as a distinct research compound follows from exactly that shift.

Honest framing of the evidence

Both compounds have limited published human data relative to how widely they are discussed, and much of the available literature is mechanistic. Reported effects in the published record are generally modest and remain debated. Secondary sources frequently present both compounds with far more confidence than the primary literature supports, and that gap is worth keeping in view when reading about either.

The wider family

Melanotan I sits alongside both as the MC1R-selective member of the group, which completes the picture: one selective compound, one non-selective compound, and one derivative with a shifted profile. Comparing any two of them without accounting for receptor selectivity misses the distinction that actually separates them.